The World Desk · slice 04
Health & Bio Desk
Regulatory decisions, clinical trials, and the oncology literature. This desk keeps the health slice of our record, from FDA actions to published research. Each finding shows how many separate publishers carried it.
$1.6T: annual sales of the global pharmaceutical market — industry estimates. On this desk’s wire right now: $19M in federal award records.
What this desk is
Regulatory decisions, clinical-trial readouts, drug and diagnostic approvals, and the oncology research frontier.
Not on this desk: Drug-enforcement and narcotics policing, dropped by name, and consumer wellness coverage that carries no clinical or regulatory finding.
- What is on the page now: 30 items from 21 sources, the earliest dated 2026-09-09. Drawn from 783 fresh items across 350 sources on this beat.
- How often it changes: rebuilt every snapshot; as of 2026-11-02.
- Daily brief: none yet. This desk has no daily brief; the page itself is the desk, rebuilt every snapshot.
- How a tier is earned: A tier is earned by independent origins, not by volume: each newsroom that reported an event on its own counts once, and every syndicated copy of a single wire counts once in total.
Contracts & awards
Award and solicitation records from SAM.gov and USAspending.
- MOTOROLA SOLUTIONS, INC. — $39K — Drug Enforcement Administration: Department of Justice
- COMCAST CABLE COMMUNICATIONS, LLC — $25K — Drug Enforcement Administration: Department of Justice
- LENCO INDUSTRIES, INC. — $2.2M — Drug Enforcement Administration: Department of Justice
- TEXTRON AVIATION INC — $16.8M — Drug Enforcement Administration: Department of Justice
- Courier Services at Brian D. Allgood Army Community Hospital for the Department of Pathology and Pharmacy: DEFENSE HEALTH AGENCY HCD WEST · Award Notice
- Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance: NATIONAL INSTITUTES OF HEALTH OLAO · Presolicitation · closes 2026-11-09
Also tracked on this desk
Subjects whose coverage concentrates in this desk’s domains. Each count is the number of stories in our archive.
Our read
What more than one publisher carried on this desk between 2026-10-27 and 2026-11-02, as of 2026-11-02. The count is publishers: a wire story picked up by fifteen outlets counts once.
Carried by more than one publisher Measured
No event on this desk had more than one publisher in the window.
Changed since the last snapshot Measured
- Nothing entered or left this desk’s corroborated list since the last snapshot.
Not yet read on this desk: single-publisher events; contradictions. Not yet read is not the same as none.
This counts how many separate publishers carried an event. It does not show whether the event is true. Many outlets repeating one official statement still rest on one source. The whole week’s corroborated record.
In the coverage
What this desk’s sources reported most recently, newest first: the links behind the read above. Distilled from 783 fresh items across 350 sources on this desk’s beat; the full record feeds every desk, and these are the top reads.
- US FDA approves generic twice-yearly HIV prevention shot
- [APPROVAL] FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
- [APPROVAL] FDA Launches New Program to Advance Neuroscience Medical Product Development
- [APPROVAL] FDA Approves First Once-Weekly Insulin for Type 2 Diabetes Mellitus in Pediatric Patients
- [APPROVAL] What's New Related to Drugs
- Iowa Governor Candidate Calls for Pulling COVID Vaccine as Fall Shots Remain FDA-Approved
- The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study.
- Moleculin Biotech Completes Dosing in Phase 2/3 MIRACLE Trial for AnnAraC
- KXCO's FDA Ontology Ranked INO-3107 First. The FDA Approved It.
- FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
- Abbott’s paravalvular leak treatment secures FDA approval
- FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations
- A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with
- USFDA Oncology Drug Approvals from 2014- 2025: Comparing non-immunotherapy and immunotherapy approvals, their endpoints, and their efficacy.
- Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.
- Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
- FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indicati
- Alcon ponies up $550M for Neurotech, bagging approved cell therapy implant Encelto
- Cosette lands FDA approval for Evoxac liquid in Sjögren’s disease
- Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II Trial.
- A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years.
- Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drug
- Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting PLK1 to Impair CEP55-ESCRT-Associated Vesicular Damage Clearance.
- Nouscom raises $135M for pivotal trial of cancer-preventing vaccine candidate
Ask the record
No subject on this desk was carried by more than one publisher in the current window, so there is no question to suggest. Ask a question of the record about any subject.
Follow the Health & Bio Desk
This desk has no daily brief yet. The page is rebuilt with every snapshot and shows what more than one publisher carried and what changed since the last one. Leave your address and we will write once, when the Health & Bio Desk brief starts. Nothing else is sent.
Informational only, not investment advice. Market-size figures are editorial estimates with sources as noted; contract and award lines are drawn from public federal records via our tracked pipelines.